Ara
Toplam kayıt 3, listelenen: 1-3
Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database
(NLM (Medline), 2022)
OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This ...
Are There Any Clues to Predict Bamboo Spine in Axial Spondyloarthritis?
(Wiley, 2020)
[No Abstract Available]
Leflunomide as a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(Wiley, 2018)
[No Abstract Available]